ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,843Medicare Part D Prescriptions Filled, Including Refills

Rank: 81 out of 761

$481K Total Retail Price of All Prescriptions

Rank: 141 out of 761

488 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 488 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

16% of this provider’s 488 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 9,915 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
SIMVASTATIN 518 497 1 2
ATORVASTATIN CALCIUM 501 456 2 12
ATENOLOL 442 429 3 8
LEVOTHYROXINE SODIUM 368 343 4 3
HYDROCHLOROTHIAZIDE 351 339 5 11
FUROSEMIDE 348 332 6 7
LISINOPRIL 337 279 7 1
POTASSIUM CHLORIDE 316 301 8 18
OMEPRAZOLE 293 266 9 4
HYDROCODONE-ACETAMINOPHEN 288 263 S3 10 5
LOSARTAN POTASSIUM 250 238 11 13
AMLODIPINE BESYLATE 245 237 12 6
METFORMIN HCL 233 190 13 10
LOVASTATIN 197 162 14 17
GLIPIZIDE 187 167 15 39
PRAVASTATIN SODIUM 175 172 16 20
ENALAPRIL MALEATE 149 141 17 71
GABAPENTIN 146 135 18 15
METOPROLOL SUCCINATE 144 126 19 16
WARFARIN SODIUM 144 136 19 9
CITALOPRAM HBR 143 105 21 19
FELODIPINE ER 140 135 22 108
ALLOPURINOL 126 126 23 28
PROAIR HFA 121 92 24 32
FLUOXETINE HCL 118 105 25 31
PANTOPRAZOLE SODIUM 113 92 26 40
ALENDRONATE SODIUM 113 110 26 21
BENAZEPRIL HCL 112 100 28 112
DOXAZOSIN MESYLATE 96 86 29 55
FLUTICASONE PROPIONATE 94 93 30 29
PREDNISONE 88 83 31 30
GEMFIBROZIL 86 66 32 116
TRAZODONE HCL 84 62 33 23
LEVOXYL 84 79 33 96
ACTOS 83 83 35 151
DONEPEZIL HCL 80 80 36 33
SERTRALINE HCL 79 61 37 25
NAMENDA 75 75 38 59
ADVAIR DISKUS 65 57 39 37
SPIRONOLACTONE 63 52 40 45
CARVEDILOL 61 61 41 26
TRIAMTERENE-HCTZ 60 60 42 42
TAMSULOSIN HCL 56 55 43 27
PAROXETINE HCL 54 54 44 47
METOPROLOL TARTRATE 52 52 45 14
DIGOXIN 51 50 46 43
ESTRADIOL 51 44 R 46 80
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 15, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.